Do analysts recommend NNNN or PROF?

Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 96.25%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher earnings & valuation, NNNN or PROF?

Anbio Biotechnology has higher earnings, but lower revenue than Profound Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 87.33 $6.40M N/A N/A Profound Medical $16.10M 13.30 -$42.57M -$0.98 N/A

Which has better valuation and earnings, PROF or INMD?

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profound Medical $16.10M 13.30 -$42.57M -$0.98 N/A InMode $370.49M 2.23 $93.83M $1.23 11.67

Is PROF or INMD more profitable?

InMode has a net margin of 20.69% compared to Profound Medical's net margin of -171.57%. InMode's return on equity of 11.99% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets Profound Medical -171.57% -63.03% -51.24% InMode 20.69% 11.99% 10.60%

Profound Medical (PROF) Competitors

$5.86 -0.03 (-0.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.84 -0.02 (-0.26%)

As of 09/18/2026 07:30 PM Eastern

Compare

PROF vs. CBLL, NNNN, AVR, BBNX, and INMD

Should you buy Profound Medical stock or one of its competitors? Profound Medical's main competitors and comparable companies include CeriBell (CBLL), Anbio Biotechnology (NNNN), Anteris Technologies Global (AVR), Beta Bionics (BBNX), and InMode (INMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Profound Medical compare to CeriBell?

Profound Medical (NASDAQ:PROF) and CeriBell (NASDAQ:CBLL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

CeriBell has a net margin of -64.73% compared to Profound Medical's net margin of -171.57%. CeriBell's return on equity of -44.85% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
CeriBell	-64.73%	-44.85%	-35.69%

Profound Medical currently has a consensus price target of $11.50, suggesting a potential upside of 96.25%. CeriBell has a consensus price target of $24.40, suggesting a potential upside of 0.12%. Given Profound Medical's higher possible upside, equities analysts clearly believe Profound Medical is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Profound Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

In the previous week, CeriBell had 10 more articles in the media than Profound Medical. MarketBeat recorded 10 mentions for CeriBell and 0 mentions for Profound Medical. CeriBell's average media sentiment score of 0.56 beat Profound Medical's score of 0.03 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
Profound Medical	Neutral
CeriBell	Positive

Profound Medical has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	13.30	-$42.57M	-$0.98	N/A
CeriBell	$89.06M	10.50	-$53.41M	-$1.76	N/A

47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 17.7% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

CeriBell beats Profound Medical on 10 of the 16 factors compared between the two stocks.

How does Profound Medical compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

47.9% of Profound Medical shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Anbio Biotechnology had 1 more articles in the media than Profound Medical. MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.03 beat Anbio Biotechnology's score of -0.54 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Anbio Biotechnology	Negative
Profound Medical	Neutral

Anbio Biotechnology has a beta of 5.17, suggesting that its stock price is 417% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 96.25%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Anbio Biotechnology has a net margin of 0.00% compared to Profound Medical's net margin of -171.57%. Anbio Biotechnology's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Profound Medical	-171.57%	-63.03%	-51.24%

Anbio Biotechnology has higher earnings, but lower revenue than Profound Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	87.33	$6.40M	N/A	N/A
Profound Medical	$16.10M	13.30	-$42.57M	-$0.98	N/A

Summary

Profound Medical beats Anbio Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Profound Medical compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Profound Medical has higher revenue and earnings than Anteris Technologies Global. Profound Medical is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	416.37	-$94.14M	-$1.95	N/A
Profound Medical	$16.10M	13.30	-$42.57M	-$0.98	N/A

Anteris Technologies Global presently has a consensus price target of $16.00, indicating a potential upside of 96.08%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 96.25%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts clearly believe Profound Medical is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Anteris Technologies Global had 2 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for Anteris Technologies Global and 0 mentions for Profound Medical. Anteris Technologies Global's average media sentiment score of 1.15 beat Profound Medical's score of 0.03 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Overall Sentiment
Anteris Technologies Global	Positive
Profound Medical	Neutral

Anteris Technologies Global has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

Profound Medical has a net margin of -171.57% compared to Anteris Technologies Global's net margin of -4,619.27%. Profound Medical's return on equity of -63.03% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%
Profound Medical	-171.57%	-63.03%	-51.24%

47.9% of Profound Medical shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Profound Medical beats Anteris Technologies Global on 10 of the 17 factors compared between the two stocks.

How does Profound Medical compare to Beta Bionics?

Profound Medical (NASDAQ:PROF) and Beta Bionics (NASDAQ:BBNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Beta Bionics had 73 more articles in the media than Profound Medical. MarketBeat recorded 73 mentions for Beta Bionics and 0 mentions for Profound Medical. Beta Bionics' average media sentiment score of 0.24 beat Profound Medical's score of 0.03 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Overall Sentiment
Profound Medical	Neutral
Beta Bionics	Neutral

47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profound Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.37, suggesting that its share price is 237% more volatile than the broader market.

Beta Bionics has a net margin of -61.31% compared to Profound Medical's net margin of -171.57%. Beta Bionics' return on equity of -26.30% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
Beta Bionics	-61.31%	-26.30%	-23.25%

Profound Medical presently has a consensus target price of $11.50, indicating a potential upside of 96.25%. Beta Bionics has a consensus target price of $21.90, indicating a potential upside of 0.05%. Given Profound Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Profound Medical is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Profound Medical has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	13.30	-$42.57M	-$0.98	N/A
Beta Bionics	$100.25M	9.82	-$73.20M	-$1.65	N/A

Summary

Beta Bionics beats Profound Medical on 9 of the 17 factors compared between the two stocks.

How does Profound Medical compare to InMode?

Profound Medical (NASDAQ:PROF) and InMode (NASDAQ:INMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, InMode had 2 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for InMode and 0 mentions for Profound Medical. InMode's average media sentiment score of 0.65 beat Profound Medical's score of 0.03 indicating that InMode is being referred to more favorably in the news media.

Company	Overall Sentiment
Profound Medical	Neutral
InMode	Positive

InMode has a net margin of 20.69% compared to Profound Medical's net margin of -171.57%. InMode's return on equity of 11.99% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
InMode	20.69%	11.99%	10.60%

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	13.30	-$42.57M	-$0.98	N/A
InMode	$370.49M	2.23	$93.83M	$1.23	11.67

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profound Medical currently has a consensus price target of $11.50, indicating a potential upside of 96.25%. InMode has a consensus price target of $16.00, indicating a potential upside of 11.50%. Given Profound Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Profound Medical is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Profound Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, InMode has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market.

Summary

InMode beats Profound Medical on 12 of the 16 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROF vs. The Competition

Export

Metric	Profound Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$214.08M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-5.98	25.34	275.49	25.40
Price / Sales	13.30	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	3.20	5.69	10.46	6.33
Net Income	-$42.57M	$151.55M	$3.49B	$358.33M
7 Day Performance	-1.84%	0.66%	0.59%	1.12%
1 Month Performance	-11.88%	-3.33%	-1.74%	-2.39%
1 Year Performance	35.02%	6.79%	18.13%	5.35%

Profound Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROF Profound Medical	2.3841 of 5 stars	$5.86 -0.5%	$11.50 +96.2%	+35.0%	$214.08M	$16.10M	N/A	162
CBLL CeriBell	1.895 of 5 stars	$24.31 -1.7%	$24.40 +0.4%	+98.9%	$948.71M	$89.06M	N/A	N/A	News Coverage Insider Trade
NNNN Anbio Biotechnology	0.24 of 5 stars	$6.48 -0.9%	N/A	N/A	$941.05M	$8.65M	N/A	27
AVR Anteris Technologies Global	2.5929 of 5 stars	$8.62 -4.6%	$16.00 +85.6%	+55.7%	$881.03M	$1.91M	N/A	138	Positive News
BBNX Beta Bionics	1.0337 of 5 stars	$19.33 -0.5%	$20.10 +4.0%	-2.5%	$873.70M	$100.25M	N/A	294	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROF) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Competitors

PROF vs. CBLL, NNNN, AVR, BBNX, and INMD

How does Profound Medical compare to CeriBell?

Summary

How does Profound Medical compare to Anbio Biotechnology?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Summary

How does Profound Medical compare to Beta Bionics?

Summary

How does Profound Medical compare to InMode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Competitors

PROF vs. CBLL, NNNN, AVR, BBNX, and INMD

How does Profound Medical compare to CeriBell?

Is PROF or CBLL more profitable?

Do analysts rate PROF or CBLL?

Which has more volatility and risk, PROF or CBLL?

Does the media favor PROF or CBLL?

Which has higher valuation & earnings, PROF or CBLL?

Do institutionals & insiders hold more shares of PROF or CBLL?

Summary

How does Profound Medical compare to Anbio Biotechnology?

Do institutionals and insiders hold more shares of NNNN or PROF?

Does the media favor NNNN or PROF?

Which has more volatility and risk, NNNN or PROF?

Do analysts recommend NNNN or PROF?

Is NNNN or PROF more profitable?

Which has higher earnings & valuation, NNNN or PROF?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Which has higher earnings & valuation, AVR or PROF?

Do analysts prefer AVR or PROF?

Does the media prefer AVR or PROF?

Which has more risk & volatility, AVR or PROF?

Is AVR or PROF more profitable?

Do institutionals & insiders have more ownership in AVR or PROF?

Summary

How does Profound Medical compare to Beta Bionics?

Does the media favor PROF or BBNX?

Do institutionals and insiders believe in PROF or BBNX?

Which has more risk and volatility, PROF or BBNX?

Is PROF or BBNX more profitable?

Do analysts prefer PROF or BBNX?

Which has better valuation & earnings, PROF or BBNX?

Summary

How does Profound Medical compare to InMode?

Does the media favor PROF or INMD?

Is PROF or INMD more profitable?

Which has better valuation and earnings, PROF or INMD?

Do insiders & institutionals believe in PROF or INMD?

Do analysts recommend PROF or INMD?

Which has more risk and volatility, PROF or INMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools